SAB Biotherapeutics (SABS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.53, -2.32% vs the prior close of $2.59.
- Volume 756.77K shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SABS dips 2.3% to $2.53. Closed at $2.53, -2.32% vs the prior close of $2.59. Day range $2.47–$2.63, opened at $2.59.
SABS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SABS dips 2.3% to $2.53
- Closed at $2.53, -2.32% vs the prior close of $2.59. Day range $2.47–$2.63, opened at $2.59.
- Volume was 756.77K shares, 1.5x its 50-day average of 515.29K.
- Price is -25.9% vs its 50-day average ($3.42) and -32.0% vs its 200-day average ($3.72).
- 52-week range $2.10–$5.15; today's close sits at 14% of that range, 50.9% below the 52-week high.
Oct 15, 2026 — SABS jumps 4.0% to $2.59
- Closed at $2.59, +4.02% vs the prior close of $2.49. Day range $2.48–$2.62, opened at $2.51.
- Volume was 787.90K shares, 1.6x its 50-day average of 505.22K.
- Price is -24.8% vs its 50-day average ($3.44) and -30.5% vs its 200-day average ($3.73).
- 52-week range $2.10–$5.15; today's close sits at 16% of that range, 49.7% below the 52-week high.
Oct 14, 2026 — SABS slides 7.1% to $2.49, a 6-month low, 3 down days in a row
- Closed at $2.49, -7.09% vs the prior close of $2.68. Day range $2.45–$2.72, opened at $2.64.
- Volume was 853.10K shares, 1.7x its 50-day average of 511.40K.
- Price is -28.2% vs its 50-day average ($3.47) and -33.3% vs its 200-day average ($3.73).
- 52-week range $2.10–$5.15; today's close sits at 13% of that range, 51.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — SABS slides 5.3% to $2.68, a 6-month low
- Closed at $2.68, -5.30% vs the prior close of $2.83. Day range $2.62–$2.88, opened at $2.84.
- Volume was 893.00K shares, 1.8x its 50-day average of 507.07K.
- Price is -23.3% vs its 50-day average ($3.49) and -28.3% vs its 200-day average ($3.74).
- 52-week range $2.10–$5.15; today's close sits at 19% of that range, 48.0% below the 52-week high.
- SEC filings that day: 8-K.
Oct 12, 2026 — SABS slides 5.0% to $2.83, a 6-month low
- Closed at $2.83, -5.03% vs the prior close of $2.98. Day range $2.80–$3.00, opened at $2.99.
- Volume was 359.00K shares, 0.7x its 50-day average of 507.99K.
- Price is -19.5% vs its 50-day average ($3.52) and -24.4% vs its 200-day average ($3.75).
- 52-week range $2.10–$5.15; today's close sits at 24% of that range, 45.0% below the 52-week high.
Oct 9, 2026 — SABS jumps 3.1% to $2.98
- Closed at $2.98, +3.11% vs the prior close of $2.89. Day range $2.81–$3.02, opened at $2.90.
- Volume was 659.60K shares, 1.3x its 50-day average of 498.97K.
- Price is -15.6% vs its 50-day average ($3.53) and -20.5% vs its 200-day average ($3.75).
- 52-week range $2.10–$5.15; today's close sits at 29% of that range, 42.1% below the 52-week high.
Oct 8, 2026 — SABS rises 0.3% to $2.89 on 2.3x normal volume
- Closed at $2.89, +0.35% vs the prior close of $2.88. Day range $2.76–$2.93, opened at $2.85.
- Volume was 1.14M shares, 2.3x its 50-day average of 483.69K — unusually heavy trading.
- Price is -18.4% vs its 50-day average ($3.54) and -23.0% vs its 200-day average ($3.76).
- 52-week range $2.10–$5.15; today's close sits at 26% of that range, 43.9% below the 52-week high.
Oct 7, 2026 — SABS dips 1.7% to $2.88, a 6-month low
- Closed at $2.88, -1.71% vs the prior close of $2.93. Day range $2.81–$2.96, opened at $2.90.
- Volume was 679.30K shares, 1.4x its 50-day average of 474.93K.
- Price is -19.0% vs its 50-day average ($3.55) and -23.4% vs its 200-day average ($3.76).
- 52-week range $2.10–$5.15; today's close sits at 26% of that range, 44.1% below the 52-week high.
Oct 6, 2026 — SABS slides 5.5% to $2.93, a 6-month low
- Closed at $2.93, -5.48% vs the prior close of $3.10. Day range $2.91–$3.16, opened at $3.12.
- Volume was 663.60K shares, 1.4x its 50-day average of 473.85K.
- Price is -17.8% vs its 50-day average ($3.57) and -22.2% vs its 200-day average ($3.77).
- 52-week range $2.06–$5.15; today's close sits at 28% of that range, 43.1% below the 52-week high.
Oct 5, 2026 — SABS jumps 4.0% to $3.10 on 1.8x normal volume
- Closed at $3.10, +4.03% vs the prior close of $2.98. Day range $2.86–$3.25, opened at $3.00.
- Volume was 866.20K shares, 1.8x its 50-day average of 475.61K — unusually heavy trading.
- Price is -13.3% vs its 50-day average ($3.58) and -17.8% vs its 200-day average ($3.77).
- 52-week range $1.97–$5.15; today's close sits at 36% of that range, 39.8% below the 52-week high.
Oct 2, 2026 — SABS dips 2.6% to $2.98, a 6-month low, 3 down days in a row
- Closed at $2.98, -2.61% vs the prior close of $3.06. Day range $2.96–$3.12, opened at $3.10.
- Volume was 415.80K shares, 0.9x its 50-day average of 485.14K.
- Price is -16.8% vs its 50-day average ($3.58) and -21.1% vs its 200-day average ($3.78).
- 52-week range $1.94–$5.15; today's close sits at 32% of that range, 42.1% below the 52-week high.
- That makes 3 straight losses.
SABS latest news & SEC filings
Every SEC filing by or about SABS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kropotova Alexandra had withheld for taxes 473 shares on Sep 17, 2026; now holds 41,853
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$22.49M (prior year -$10.11M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.28 (prior year -$1.09) (loss narrowed vs Jun 30, 2025)
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SABS
- Last results release: Mar 29, 2024 (8-K Item 2.02). Previous ones: Mar 31, 2023, Nov 22, 2021. Based on that rhythm, the next report is likely around Jun 28, 2024 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.06% (largest 7.1%). That is a volatile stock.
- Liquidity: about 762.86K shares (≈$1.93M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.53 vs a range of $2.10–$5.15 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 13, 2026; 10-Q Aug 6, 2026; 8-K Jul 7, 2026.
- Share count: 90.99M shares outstanding (Aug 3, 2026), +773.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SABS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.59 | 2.63 | 2.47 | 2.53 | 756.77K |
| Oct 15, 2026 | 2.51 | 2.62 | 2.48 | 2.59 | 787.90K |
| Oct 14, 2026 | 2.64 | 2.72 | 2.45 | 2.49 | 853.10K |
| Oct 13, 2026 | 2.84 | 2.88 | 2.62 | 2.68 | 893.00K |
| Oct 12, 2026 | 2.99 | 3.00 | 2.80 | 2.83 | 359.00K |
| Oct 9, 2026 | 2.90 | 3.02 | 2.81 | 2.98 | 659.60K |
| Oct 8, 2026 | 2.85 | 2.93 | 2.76 | 2.89 | 1.14M |
| Oct 7, 2026 | 2.90 | 2.96 | 2.81 | 2.88 | 679.30K |
| Oct 6, 2026 | 3.12 | 3.16 | 2.91 | 2.93 | 663.60K |
| Oct 5, 2026 | 3.00 | 3.25 | 2.86 | 3.10 | 866.20K |
| Oct 2, 2026 | 3.10 | 3.12 | 2.96 | 2.98 | 415.80K |
| Oct 1, 2026 | 3.15 | 3.22 | 3.04 | 3.06 | 425.50K |
| Sep 30, 2026 | 3.23 | 3.40 | 3.16 | 3.17 | 487.80K |
| Sep 29, 2026 | 3.24 | 3.31 | 3.19 | 3.22 | 1.06M |
| Sep 28, 2026 | 3.34 | 3.34 | 3.14 | 3.21 | 697.90K |
| Sep 25, 2026 | 3.36 | 3.49 | 3.27 | 3.29 | 2.45M |
| Sep 24, 2026 | 3.38 | 3.44 | 3.25 | 3.35 | 544.20K |
| Sep 23, 2026 | 3.49 | 3.55 | 3.31 | 3.39 | 406.70K |
| Sep 22, 2026 | 3.42 | 3.56 | 3.42 | 3.50 | 739.00K |
| Sep 21, 2026 | 3.51 | 3.55 | 3.39 | 3.39 | 379.10K |
About SAB Biotherapeutics
SAB Biotherapeutics (SABS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in MIAMI BEACH, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1833214.
SABS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Helen K. Ellias | Director | Dec 18, 2025 |
| Scott Giberson | Director | Dec 18, 2025 |
| Rita Jain | Director | Jan 7, 2026 |
| David Link | Director | Dec 18, 2025 |
| Erick Lucera | Director | Dec 18, 2025 |
| Andrew Moin | Director | Oct 1, 2025 |
| John Petry | Director | Oct 1, 2025 |
| William James Polvino | Director | Dec 18, 2025 |
| Samuel J Reich | CEO | Feb 5, 2026 |
| Jay S Skyler | Director | Dec 18, 2025 |
| Capital (Master), L.P. Sessa | Director | Oct 1, 2025 |
| Capital Gp, Llc Sessa | Director | Oct 1, 2025 |
| Capital Im Gp, Llc Sessa | Director | Oct 1, 2025 |
| Capital Im, L.P. Sessa | Director | Oct 1, 2025 |
| Eddie Joe Sullivan | PRESIDENT | Feb 5, 2026 |
| David Zaccardelli | Director | Jan 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | Feb 5, 2026 |
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | Sep 18, 2026 |
| Samuel J Reich | CEO | Feb 5, 2026 |
| Eddie Joe Sullivan | PRESIDENT | Feb 5, 2026 |
| Lucy To | See Remarks | Feb 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
SABS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $13.27M | -0.79 | $-44.78M |
| Dec 31, 2024 | $1.32M | $-34.11M | -3.68 | $-34.29M |
| Dec 31, 2023 | $2.24M | $-42.19M | -7.64 | $-25.12M |
| Dec 31, 2022 | $23.90M | $-18.74M | -4.31 | $-23.46M |
| Dec 31, 2021 | $60.88M | $-17.14M | -0.63 | $1.99M |
Latest balance sheet: total assets $238.21M, total liabilities $23.43M, cash $8.27M (as of Jun 30, 2026).
SABS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 29, 2024 | 8-K Item 2.02 (results) | — |
| Mar 31, 2023 | 8-K Item 2.02 (results) | — |
| Nov 22, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SABS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.